KREJČÍ, Marta, Luděk POUR, Zdeněk ADAM, Viera SANDECKÁ, Martin ŠTORK, Sabina ŠEVČÍKOVÁ, Martin KREJČÍ, Zdeňka KNECHTOVÁ a Zdeněk KRÁL. Outcome of COVID-19 infection in 50 multiple myeloma patients treated with novel drugs: single-center experience. Annals of hematology. New York: Springer Verlag, roč. 100, č. 10, s. 2541-2546. ISSN 0939-5555. doi:10.1007/s00277-021-04594-w. 2021.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Outcome of COVID-19 infection in 50 multiple myeloma patients treated with novel drugs: single-center experience
Autoři KREJČÍ, Marta (203 Česká republika, garant, domácí), Luděk POUR (203 Česká republika, domácí), Zdeněk ADAM (203 Česká republika, domácí), Viera SANDECKÁ (703 Slovensko, domácí), Martin ŠTORK (203 Česká republika, domácí), Sabina ŠEVČÍKOVÁ (203 Česká republika, domácí), Martin KREJČÍ (203 Česká republika, domácí), Zdeňka KNECHTOVÁ (203 Česká republika) a Zdeněk KRÁL (203 Česká republika, domácí).
Vydání Annals of hematology, New York, Springer Verlag, 2021, 0939-5555.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30205 Hematology
Stát vydavatele Spojené státy
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 4.030
Kód RIV RIV/00216224:14110/21:00122810
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.1007/s00277-021-04594-w
UT WoS 000678464700001
Klíčová slova anglicky Multiple myeloma; COVID-19; Novel drugs; Hospitalization; Mortality
Štítky 14110212, 14110518, rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Tereza Miškechová, učo 341652. Změněno: 12. 10. 2022 17:53.
Anotace
Infections are the primary cause of morbidity and mortality in multiple myeloma (MM) patients (pts). The aim of our retrospective analysis was to evaluate incidence and course of COVID-19 infection in a cohort of 351 MM outpatients treated with novel drugs. COVID-19 disease was detected in 50/351 pts (14%); median age was 68 years. Gender, ISS stage, and last treatment lines were as follows: male 32, female 18; ISS-I 19, ISS-II 20, ISS-III 11; daratumumab-based 15, lenalidomide-based 12, bortezomib-based 17, other 6. Positive PCR test at COVID-19 diagnosis was present in all pts; anti-myeloma treatment was interrupted. Hospitalizations for COVID-19 pneumonia were necessary for 28/50 pts (56%), 18/50 pts (36%) in standard unit (SU) 10/50 pts (20%) in intensive care unit (ICU), and 9/50 pts (18%) died. The statistically significant parameters for COVID-19 hospitalization were as follows: responsive versus non-responsive disease (p = 0.027), ECOG performance status 0-2 versus >= 3 (p = 0.014), presence of comorbidities (0-1 versus >= 2, p = 0.043). The statistically significant factors for COVID-19 death were as follows: ECOG 0-2 versus >= 3 (p = 0.001), presence of comorbidities (0-1 versus >= 2, p = 0.007), serious course of COVID-19 disease with ICU hospitalization (SU versus ICU, p = 0.001). None of the other studied risk factors was associated with poor outcome (age, gender, ISS stage, immunoparesis, type of anti-myeloma treatment). Full recovery from COVID-19 infection was observed in 41/50 pts (82%) in median of 32 days. The course of COVID-19 disease in MM pts was mostly moderate or serious with 56% of hospitalizations and 18% of deaths.
VytisknoutZobrazeno: 28. 3. 2024 11:35